Serum Institute’s HPV vaccine Cervavac receives WHO prequalification
Inclusion on the WHO list allows Cervavac to be procured by U.N. agencies. The vaccine targets four HPV types and is indicated for girls and boys aged 9 through 26 years
Serum Institute of India's HPV vaccine Cervavac has received prequalification from the World Health Organization (WHO). This vaccine targets HPV types 6, 11, 16, and 18, which are responsible for various cancers and genital warts. Cervavac is approved for use in individuals aged 9 to 26 years, both boys and girls. The inclusion in the WHO prequalified vaccines list enables the vaccine to be procured by UN agencies.
Developed in collaboration with the Department of Biotechnology, Biotechnology Industry Research Assistance Council, WHO-IARC, and the Gates Foundation, Cervavac marks the 32nd WHO prequalification for Serum Institute, a leading vaccine manufacturer. CEO Adar Poonawalla expressed satisfaction with the achievement and highlighted the importance of Cervavac in strengthening global HPV response.
Cervavac has been approved for use in India by the Drugs Controller General of India (DCGI) and is administered intramuscularly in 0.5 ml or 1.0 ml vials.
Written by urgent.news from The Hindu - Sci-Tech's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
